Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13343-13368
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13343
Table 6 Ongoing clinical trials of gene therapy in pancreatic cancer
PhaseTransgenes
IOncolytic adenovirus and oncolytic herpesvirus1
Somatostatin receptor 2 (sst2), Deoxycitidine kinase :: uridylmonophosphate kinase (dck::umk)
Somatostatin receptor 2 (sst2)
Mesothelin-scFv with signaling domains comprised of TCR , CD28, and 4-1BB (CD137) cDNA
GM-CSF
PANVAC (CEA, MUC-1, and TRICOM)
Cytosine deaminase, Herpes simplex virus thymidine kinase (HSV-TK)
Cyclin G1
p53
BikDD (DOTAP-cholesterol mediated gene transfection)
Mutated Ras
I/IICytochrome p450
AEG 35156: antisense oligonucleotide to X-linked inhibitor of apoptosis protein (XIAP)
Herpes simplex virus thymidine kinase (HSV-TK)
Diphtheria Toxin A Chain (DTA) gene with H19 promoter
Alpha-(1,3) galactosyltransferase
IICEA, MUC-1, and PANVAC
Mutated Ras
Alpha-(1,3) galactosyltransferase
IIIAlpha-(1,3) galactosyltransferase
PANVAC (CEA, MUC-1, and TRICOM)2